Relapsed or Refractory Lymphomas | Norton Healthcare

Indication: Relapsed or Refractory Lymphomas

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia and Solid Tumors

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Kymera Therapeutics, Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.